Objective: Contact hypersensitivity (CHS), or allergic contact dermatitis (ACD), is an inflammatory skin disorder characterized by an exaggerated allergic reaction to specific haptens. During this delayed-type allergic reaction, the first contact with the allergen initiates the sensitization phase, forming memory T cells. Upon repeated contact with the hapten, the elicitation phase develops, activating mostly macrophages, cytotoxic T cells, and neutrophilic granulocytes. Our group previously demonstrated that the leukocyte-specific GTPase-activating protein ARHGAP25 regulates phagocyte effector functions and is crucial in the pathomechanism of autoantibody-induced arthritis. Here, we investigate its role in the pathogenesis of the more complex inflammatory process of contact hypersensitivity.

Methods: For sensitization, the abdomens of wild-type and ARHGAP25 deficient (KO) mice on a C57BL/6 background, as well as bone marrow chimeric mice, were coated with 3% TNCB (2-chloro-1,3,5-trinitrobenzene) or acetone in the control group. After five days, ears were treated with 1% TNCB for elicitation. Swelling of the ears caused by edema formation was evaluated by measuring the ear thickness. Afterward, ears were harvested, and histological analysis, investigation of leukocyte infiltration, cytokine production, and changes in relevant signaling pathways were carried out. ARHGAP25 expression at the mRNA and protein levels was measured using murine ear and human skin samples.

Results: ARHGAP25 expression increased in human patients suffering from contact dermatitis and in contact hypersensitivity induced in mice. Our data suggest that ARHGAP25 expression is infinitesimal in keratinocytes. In the CHS mouse model, the absence of ARHGAP25 mitigated the severity of inflammation in a leukocyte-dependent manner by reducing the infiltration of phagocytes and cytotoxic T cells. ARHGAP25 altered cytokine composition in the sensitization and elicitation phase of the disease. However, this protein did not affect T cell homing and activation in the sensitization phase.

Conclusion: Our findings suggest that ARHGAP25 is essential in developing contact hypersensitivity by modulating the cytokine environment and leukocyte infiltration. Based on these findings, we propose ARHGAP25 as a promising candidate for future therapeutic approaches and a potential ACD biomarker.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896868PMC
http://dx.doi.org/10.3389/fimmu.2025.1509713DOI Listing

Publication Analysis

Top Keywords

contact hypersensitivity
16
arhgap25 expression
12
arhgap25
10
contact
9
allergic contact
8
contact dermatitis
8
allergic reaction
8
elicitation phase
8
cytotoxic cells
8
leukocyte infiltration
8

Similar Publications

Objective: Contact hypersensitivity (CHS), or allergic contact dermatitis (ACD), is an inflammatory skin disorder characterized by an exaggerated allergic reaction to specific haptens. During this delayed-type allergic reaction, the first contact with the allergen initiates the sensitization phase, forming memory T cells. Upon repeated contact with the hapten, the elicitation phase develops, activating mostly macrophages, cytotoxic T cells, and neutrophilic granulocytes.

View Article and Find Full Text PDF

Biomarkers to aid in diagnosis of allergic contact dermatitis.

Front Allergy

February 2025

Department of Pathology, Microbiology, & Immunology, New York Medical College, Valhalla, NY, United States.

Allergic contact dermatitis (ACD) is an increasingly common skin condition characterized by itchy rashes in response to allergens. The most common diagnostic test involves patch testing (PT), but despite the efficacy of PT for identifying and guiding patients toward avoidance of allergens, PT alone does not elucidate the underlying biomechanistic changes which may be useful for sub-categorizing ACD further. In addition, some patients may never be able to identify their causative allergens unless they go to highly specialized ACD centers.

View Article and Find Full Text PDF

The Usefulness of Scratch-Patch Testing in Imatinib-Induced DRESS Syndrome.

Contact Dermatitis

March 2025

Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, INFLA-MED Centre of Excellence, University of Antwerp, Antwerp, Belgium.

View Article and Find Full Text PDF

Exploring new horizons in allergic contact dermatitis treatment: the role of emerging therapies.

Actas Dermosifiliogr

March 2025

Contact Eczema and Immunoallergic Diseases Department. Dermatology, Spain; Dermatology Department. Hospital Universitario San Cecilio, Granada. Spain; Instituto de Investigación Biosanitaria ibs, Granada, Spain. Electronic address:

The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes treatment challenging. With advances in the understanding of the cellular and molecular pathogenesis of this dermatosis, new therapeutic options are emerging. In particular, the use of biologic drugs such as dupilumab and small molecule inhibitors, such as JAK inhibitors have gained momentum given the cross-cutting inhibition of multiple cytokine actions.

View Article and Find Full Text PDF

Purpose: The use of ultra hypofractionated adjuvant breast radiotherapy for elderly patients was extended during the covid-19 pandemic. We compared its efficacy and safety versus moderate hypofractionation in elderly patients with breast cancer receiving locoregional radiotherapy at a single radiotherapy centre.

Methods: This retrospective analysis utilized routine patient data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!